Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 87 of 6351
-
One shot to save sight? gene therapy aims to cut eye injections for wet AMD
Disease control OngoingA Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase 3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
A new radiation combo may spare the rectum in early cancer
Disease control Recruiting nowThe aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).
Sponsor: Alexander Valdman • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
A simple nasal spray might shield the brain after heart surgery
Prevention Recruiting nowDelirium is a common consequence of cardiac surgery and associates with poor outcomes. Multiple causes can trigger delirium occurence, and it has been hypothesised that sleep disturbances can be one of them. Dexmedetomidine may be effective in reducing delirium. The aim of this s…
Phase 3 • Sponsor: Xijing Hospital • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Can MDMA-Assisted therapy rewire the traumatized brain?
Disease control Recruiting nowThis randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD o…
Phase 2 • Sponsor: Stephen Robert Marder • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for stomach cancer: phase 3 trial tests rilvegostomig combo
Disease control Recruiting nowThis is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitre…
Phase 3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New lung cancer drug ivonescimab takes on pembrolizumab in major trial
Disease control Recruiting nowClinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Phase 3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for stomach cancer: enhertu combo takes on tough tumors
Disease control Recruiting nowThis clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-lin…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could common drugs curb brain bleed aftermath?
Disease control Recruiting nowThis is a domain within the ACT-GLOBAL platform trial to compare the effectiveness of early and appropriate pharmacological interventions in acute intracerebral hemorrhage (ICH) to control secondary brain injury. Up to 2000 patients with presumed spontaneous supratentorial intrac…
Phase 3 • Sponsor: The George Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThe Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Exte…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug duo aims to outperform standard pill for common lung cancer
Disease control Recruiting nowThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell L…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
First-in-Human trial aims to offer new hope for patients with leaky heart valves who Can't have surgery
Disease control Recruiting nowThis study is a prospective, multi-center, non-randomized first in human study to evaluate the safety and feasibility of the Capstan Medical TMVR System for intervention in adults with moderate-severe or greater mitral regurgitation who are not surgical candidates.
Sponsor: Capstan Medical • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Triple threat: new combo aims to tackle tough breast cancer
Disease control Recruiting nowThis study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objectiv…
Phase 3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Chemo plaque could spare Kids' eyes from removal
Disease control Recruiting nowIn this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. T…
Phase 2 • Sponsor: Targeted Therapy Technologies, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Triple-Drug cocktail aims to make inoperable liver cancer removable
Disease control Recruiting nowThe purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
Phase 2/3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could this new vaccine end tuberculosis?
Vaccine OngoingA Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.
Phase 2 • Sponsor: International AIDS Vaccine Initiative • Aim: Vaccine
Last updated Sep 10, 2026 02:00 UTC
-
Simple blood test could spot lung cancer early in heavy smokers
Diagnosis Recruiting nowThe goal of this observational study is to develop and evaluate a blood test for asymptomatic heavy smokers to screen for those at highest risk of developing lung cancer. The aim of this study is to develop, train, and validate a blood-based screening test designed to detect biom…
Sponsor: Everest Detection, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
New pill aims to cut sickle cell pain crises in half
Disease control Recruiting nowThis study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial
Prevention Recruiting nowThis is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the curr…
Phase 4 • Sponsor: University of Oxford • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
Engineered immune cells show promise in Hard-to-Treat leukemia
Disease control Recruiting nowThe safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from the ATHENA trial (NCT06014073). Unexpect…
Phase 1/2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC